- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02368327
Gene Expression Profiles in Muscle After Immunisation
August 7, 2015 updated by: University of Surrey
Clinical Study to Generate Exploratory Training Set of Data on the Time Course of Gene Expression Profile at Site of Antigen Deposition Compared With Whole Blood Following IM Injection With Alum or MF59-adjuvanted Protein Subunit Vaccines
This clinical study is part of the BIOVACSAFE project which is funded by the Innovative Medicine Initiative.
In this study we will take a small muscle biopsy in order to identify any differences in the response around the actual site of injection compared with responses we measure in blood at the same time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XP
- Surrey Clinical Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- The participant is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The participant has signed the ICF.
- Healthy male participants aged 18-45 years inclusive.
- BMI between 19-27 kg/m2.
- Pre-immunised with Hepatitis B vaccine
- Hepatitis B sAb positive (evidence of vaccine-induced immunity)
- Hepatitis B sAg and cAb negative (evidence of lack of prior/current HBV infection)
- Hepatitis C and HIV seronegative.
- Available for follow-up for the duration of the study.
- Agree to abstain from donating blood during the study.
- The participant is, in the opinion of the investigator, healthy on the basis of a, medical history, a symptom directed medical examination and vital signs.
Exclusion Criteria:
- History of hypersensitivity to any of the vaccine components or a history of any allergy that in the opinion of the investigator would contraindicate participant participation
- Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological (particularly myasthenia gravis), immunological, or haematological disease or abnormality, as determined by the study physician.
- Known immune or coagulation disorder or clinically significant abnormalities of platelets, Hb or coagulation on screening labs
- Known allergy to injected local anaesthetics
- Unwilling to undergo muscle biopsies
- Use of steroids or immunosuppressive/immunomodulating drugs either orally or parenterally within 3 months of visit 1.
- Currently participating in a clinical trial with an investigational or non- investigational drug or device, or has participated in another clinical trial within the 3 months preceding the study.
- Any condition that, in the investigator's opinion, compromises the participant's ability to meet protocol requirements or to complete the study.
- Receipt of blood products or immunoglobin, within 3 months of visit 1.
- Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fluad
Participants receive one dose of Fluad vaccine
|
|
Active Comparator: Fendrix
Participants receive one dose of Fendrix vaccine
|
|
Placebo Comparator: Placebo
Participants receive one dose of saline placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline values of gene expression in whole blood and muscle
Time Frame: Day 0, Day 0+3 hours, Day 1, Day 3, Day 5 and Day 7
|
Day 0, Day 0+3 hours, Day 1, Day 3, Day 5 and Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Aldona Greenwood, University of Surrey
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
February 13, 2015
First Submitted That Met QC Criteria
February 13, 2015
First Posted (Estimate)
February 23, 2015
Study Record Updates
Last Update Posted (Estimate)
August 10, 2015
Last Update Submitted That Met QC Criteria
August 7, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- CRC305E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States